Cerebrospinal fluid and plasma pharmacokinetics of morphine infusions in pediatric cancer patients and rhesus monkeys. 1987

Raymond F Greene, and Angela W Miser, and Cindy M Lester, and Frank M Balis, and David G Poplack
Department of Pharmacology, George Washington University Medical Center, Washington, DC, USA Clinical Pharmacology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 U.S.A. Pediatrie Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 U.S.A.

The cerebrospinal fluid (CSF) and plasma pharmacokinetics of morphine administered as a continuous infusion were studied in pediatric cancer patients and in monkeys with implanted Ommaya reservoirs. In monkeys administered a constant infusion of 0.15 mg morphine sulfate/kg/h, morphine steady-state plasma and CSF concentrations were 84.4 +/- 20.0 ng/ml and 25.3 +/- 4.9 ng/ml, respectively, for a CSF:plasma ratio of 0.30 +/- 0.05. For comparison, the monkeys also received morphine as an intravenous bolus at a dose of 0.45 mg morphine sulfate/kg. The CSF:plasma area under the concentration-time curve (AUC) ratio was 0.40 +/- 0.07, similar to that seen with continuous infusion. Morphine pharmacokinetics were also studied in cancer patients administered long-term infusions of morphine sulfate over a wide dosage range (0.04-31 mg/kg/h). The steady-state plasma concentration of morphine was linearly related to the infusion rate although variability was noted. The average clearance value was 23 ml/min/kg which is at the upper end of the estimates reported for morphine clearance using bolus administration. No evidence for morphine accumulation using long-term administration was observed. A limited number of CSF samples obtained by lumbar puncture showed comparable CSF and plasma concentrations of unbound morphine assuming morphine is approximately 30% bound in human plasma.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008253 Macaca mulatta A species of the genus MACACA inhabiting India, China, and other parts of Asia. The species is used extensively in biomedical research and adapts very well to living with humans. Chinese Rhesus Macaques,Macaca mulatta lasiota,Monkey, Rhesus,Rhesus Monkey,Rhesus Macaque,Chinese Rhesus Macaque,Macaca mulatta lasiotas,Macaque, Rhesus,Rhesus Macaque, Chinese,Rhesus Macaques,Rhesus Macaques, Chinese,Rhesus Monkeys
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D009020 Morphine The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. Morphine Sulfate,Duramorph,MS Contin,Morphia,Morphine Chloride,Morphine Sulfate (2:1), Anhydrous,Morphine Sulfate (2:1), Pentahydrate,Oramorph SR,SDZ 202-250,SDZ202-250,Chloride, Morphine,Contin, MS,SDZ 202 250,SDZ 202250,SDZ202 250,SDZ202250,Sulfate, Morphine
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001693 Biological Transport, Active The movement of materials across cell membranes and epithelial layers against an electrochemical gradient, requiring the expenditure of metabolic energy. Active Transport,Uphill Transport,Active Biological Transport,Biologic Transport, Active,Transport, Active Biological,Active Biologic Transport,Transport, Active,Transport, Active Biologic,Transport, Uphill

Related Publications

Raymond F Greene, and Angela W Miser, and Cindy M Lester, and Frank M Balis, and David G Poplack
May 1985, Cancer research,
Raymond F Greene, and Angela W Miser, and Cindy M Lester, and Frank M Balis, and David G Poplack
June 1995, Antimicrobial agents and chemotherapy,
Raymond F Greene, and Angela W Miser, and Cindy M Lester, and Frank M Balis, and David G Poplack
June 1982, Cancer treatment reports,
Raymond F Greene, and Angela W Miser, and Cindy M Lester, and Frank M Balis, and David G Poplack
January 1991, Developmental pharmacology and therapeutics,
Raymond F Greene, and Angela W Miser, and Cindy M Lester, and Frank M Balis, and David G Poplack
October 1999, Drug metabolism and disposition: the biological fate of chemicals,
Raymond F Greene, and Angela W Miser, and Cindy M Lester, and Frank M Balis, and David G Poplack
November 1981, Cancer research,
Raymond F Greene, and Angela W Miser, and Cindy M Lester, and Frank M Balis, and David G Poplack
January 1980, Journal of medical primatology,
Raymond F Greene, and Angela W Miser, and Cindy M Lester, and Frank M Balis, and David G Poplack
May 1990, Annals of neurology,
Raymond F Greene, and Angela W Miser, and Cindy M Lester, and Frank M Balis, and David G Poplack
November 1988, Arzneimittel-Forschung,
Raymond F Greene, and Angela W Miser, and Cindy M Lester, and Frank M Balis, and David G Poplack
January 1990, Chemotherapy,
Copied contents to your clipboard!